Assembly Biosciences expands ABI-6250 into cholestatic liver diseases with Phase 2 planned for Q1 2027

Assembly Biosciences announced expansion of its oral NTCP inhibitor ABI-6250 into primary biliary cholangitis and primary sclerosing cholangitis, with a Phase 2 study anticipated to initiate in Q1 2027. The expansion addresses significant unmet medical needs in cholestatic liver diseases and broadens the company's pipeline beyond its ongoing hepatitis delta virus development program.